Effect of the farnesoid X receptor agonist, obeticholic acid, in hepatocellular carcinoma: Is it NASH-dependent or -independent?

被引：1
|
作者：
Attia, Yasmeen [1 ]
Tawfiq, Rasha [1 ]
Adel, Aya [1 ]
Gibriel, Abdullah [2 ]
Hammam, Olfat [3 ]
Elmazar, Mohamed [1 ]
机构：
[1] British Univ Egypt, Dept Pharmacol, Cairo, Egypt
[2] British Univ Egypt, Dept Biochem, Cairo, Egypt
[3] Theodor Bilharz Res Inst, Dept Pathol, Cairo, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1016/S0618-8278(19)31027-8
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-282
引用
收藏
页码：E520 / E520
页数：1
相关论文
共 50 条
  • [11] Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes
    Zhang, Yuanyuan
    Jackson, Jonathan P.
    Claire, Robert L. St., III
    Freeman, Kimberly
    Brouwer, Kenneth R.
    Edwards, Jeffrey E.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (04):
  • [12] The Effects of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Patients With Chronic Diarrhea Secondary to Crohn's Ileal Disease
    Nolan, Jonathan D.
    Vassie, Claire
    Johnston, Ian M.
    Dew, Tracy
    Shapiro, David
    Walters, Julian R.
    GASTROENTEROLOGY, 2014, 146 (05) : S797 - S797
  • [13] Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
    Verbeke, Len D.
    Farre, Ricard
    Trebicka, Jonel
    Komuta, Mina
    Roskams, Tania
    Klein, Sabine
    Vander Elst, Ingrid
    Windmolders, Petra
    Vanuytsel, Tim
    Nevens, Frederik
    Laleman, Wim
    HEPATOLOGY, 2013, 58 : 294A - 295A
  • [14] The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid
    Kowdley, Kris y
    Nevens, Frederik
    Andreone, Pietro
    Luketic, Velimir A.
    Shah, Hemant
    Pencek, Richard
    Marmon, Tonya K.
    Shapiro, David
    GASTROENTEROLOGY, 2015, 148 (04) : S991 - S992
  • [15] Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model
    P. Comeglio
    S. Filippi
    E. Sarchielli
    A. Morelli
    I. Cellai
    C. Corno
    L. Adorini
    G. B. Vannelli
    M. Maggi
    L. Vignozzi
    Journal of Endocrinological Investigation, 2019, 42 : 951 - 965
  • [16] Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Mudaliar, Sunder
    Henry, Robert R.
    Sanyal, Arun J.
    Morrow, Linda
    Marschall, Hanns-Ulrich
    Kipnes, Mark
    Adorini, Luciano
    Sciacca, Cathi I.
    Clopton, Paul
    Castelloe, Erin
    Dillon, Paul
    Pruzanski, Mark
    Shapiro, David
    GASTROENTEROLOGY, 2013, 145 (03) : 574 - +
  • [17] Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model
    Comeglio, P.
    Filippi, S.
    Sarchielli, E.
    Morelli, A.
    Cellai, I.
    Corno, C.
    Adorini, L.
    Vannelli, G. B.
    Maggi, M.
    Vignozzi, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (08) : 951 - 965
  • [18] Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma
    Ozudogru, Talha
    Isik, Elvan
    Gunsar, Fulya
    Turan, Ilker
    Karasu, Zeki
    Akarca, Ulus
    JOURNAL OF HEPATOLOGY, 2024, 80 : S211 - S212
  • [19] Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma
    Kumagai, Arisa
    Fukushima, Junichi
    Takikawa, Hajime
    Fukuda, Toshio
    Fukusato, Toshio
    HEPATOLOGY RESEARCH, 2013, 43 (09) : 959 - 969
  • [20] Tid1 deficiency disrupting mitochondria to drive NASH-dependent hepatocellular carcinoma progression.
    Chang, Ching-Wen
    Chen, Yu-Syuan
    Lo, Jeng-Fan
    Wang, Xin Wei
    CANCER RESEARCH, 2021, 81 (13)
12345